Amicus Therapeutics up as UK health agency approves muscle disorder therapy

Amicus Therapeutics

15/08/2023 12:54

** Amicus Therapeutics's shares  FOLD.O  up 3.5% at $13.8
premarket
    ** UK health regulator granted marketing authorization to
co's combination therapy to treat a rare disease called Pompe
disease
    ** In 2022, U.S. FDA extended review of FOLD's combination
therapy for the second time 
    ** Pompe disease is a rare genetic condition in which the
body is unable to break down the complex sugar glycogen, leading
to a buildup of the same, which causes muscular impairment
    ** Up to Monday's close, stock was up ~9% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))